GW Pharmaceuticals PLC- (GWPH) Given a $208.00 Price Target at Cantor Fitzgerald

Cantor Fitzgerald set a $208.00 price objective on GW Pharmaceuticals PLC- (NASDAQ:GWPH) in a research note released on Monday morning. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

A number of other analysts have also recently commented on the stock. Bank of America cut their price target on shares of GW Pharmaceuticals PLC- from $160.00 to $158.00 and set a buy rating on the stock in a research report on Tuesday, November 14th. Goldman Sachs Group reissued a neutral rating and set a $124.00 price objective on shares of GW Pharmaceuticals PLC- in a research report on Friday, October 6th. ValuEngine cut shares of GW Pharmaceuticals PLC- from a hold rating to a sell rating in a research report on Monday, October 2nd. Cowen reissued an outperform rating and set a $165.00 price objective on shares of GW Pharmaceuticals PLC- in a research report on Monday, October 2nd. Finally, Leerink Swann reissued an outperform rating and set a $153.00 price objective (down previously from $160.00) on shares of GW Pharmaceuticals PLC- in a research report on Monday, October 2nd. One investment analyst has rated the stock with a sell rating, four have given a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of Buy and a consensus price target of $144.55.

Shares of GW Pharmaceuticals PLC- (GWPH) traded up $3.97 on Monday, reaching $119.41. 300,359 shares of the company’s stock were exchanged, compared to its average volume of 325,305. The company has a current ratio of 10.39, a quick ratio of 10.26 and a debt-to-equity ratio of 0.02. GW Pharmaceuticals PLC- has a twelve month low of $92.65 and a twelve month high of $136.95.

A number of institutional investors have recently added to or reduced their stakes in the stock. Alps Advisors Inc. grew its position in shares of GW Pharmaceuticals PLC- by 9.1% in the 3rd quarter. Alps Advisors Inc. now owns 24,921 shares of the biopharmaceutical company’s stock worth $2,529,000 after buying an additional 2,081 shares during the last quarter. Goldman Sachs Group Inc. grew its position in shares of GW Pharmaceuticals PLC- by 48.3% during the second quarter. Goldman Sachs Group Inc. now owns 48,559 shares of the biopharmaceutical company’s stock worth $4,868,000 after acquiring an additional 15,816 shares during the last quarter. Jennison Associates LLC grew its position in shares of GW Pharmaceuticals PLC- by 0.4% during the third quarter. Jennison Associates LLC now owns 492,480 shares of the biopharmaceutical company’s stock worth $49,982,000 after acquiring an additional 1,759 shares during the last quarter. Victory Capital Management Inc. lifted its holdings in shares of GW Pharmaceuticals PLC- by 9.2% during the second quarter. Victory Capital Management Inc. now owns 308,945 shares of the biopharmaceutical company’s stock worth $30,971,000 after purchasing an additional 25,920 shares during the period. Finally, Janus Henderson Group PLC acquired a new stake in shares of GW Pharmaceuticals PLC- during the second quarter worth $70,128,000. Institutional investors and hedge funds own 81.85% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “GW Pharmaceuticals PLC- (GWPH) Given a $208.00 Price Target at Cantor Fitzgerald” was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this story can be read at https://www.dispatchtribunal.com/2017/12/05/gw-pharmaceuticals-plc-gwph-given-a-208-00-price-target-at-cantor-fitzgerald.html.

About GW Pharmaceuticals PLC-

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).

Analyst Recommendations for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply